2020 Revenues ($USD) : $24,240,000,000
2020 R&D spend : $4,207,000,000
2020 Number of Employees : 24,000
Fiscal Year End : 12/31/2020
Key People : Robert A. Bradway, chair, president and CEO; Esteban Santos, executive vice president of operations; Peter H. Griffith, CFO; David M. Reese, executive vice president of R&D; Darryl Sleep, chief medical officer and senior vice president of global medical; Mike Zahigian, chief information officer and senior vice president; Linda H. Louie, vice president of finance and chief accounting officer; Nancy A. Grygiel, chief compliance officer; David A. Piacquad, senior vice president of business development; Elliott M. Levy, SVP, strategy, operations, Research & Development; Murdo J. Gordon, executive vice president, Global Commercial Operations; Susan Sweeney, senior vice president, global marketing, access and capabilities; Arvind K. Sood, vice president of investor relations; Lori A. Johnston, senior vice president of human resources; Jonathan P. Graham, secretary, executive VP and general counsel; Victoria H. Blatter, senior vice president of U.S. government affairs

Amgen develops medications for cardiovascular disease, oncology, bone health, neurosciences, nephrology and inflammation therapies. It has 23 commercialized drugs on the market in the U.S. Enbrel, Amgen's tumor necrosis factor blocker, has led product sales at the company since 2018. The Thousand Oaks, Calif.–based company earlier this year announced plans to acquire Rodeo Therapeutics for $721 million and Five Prime Therapeutics for $1.9 billion in cash. –DK